DORCHESTER WEALTH MANAGEMENT Co Lowers Position in Kenvue Inc. (NYSE:KVUE)

DORCHESTER WEALTH MANAGEMENT Co lessened its position in Kenvue Inc. (NYSE:KVUE) by 0.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 344,070 shares of the company’s stock after selling 3,200 shares during the quarter. Kenvue accounts for approximately 1.5% of DORCHESTER WEALTH MANAGEMENT Co’s portfolio, making the stock its 26th largest holding. DORCHESTER WEALTH MANAGEMENT Co’s holdings in Kenvue were worth $7,346,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Huntington National Bank increased its stake in Kenvue by 26.5% in the third quarter. Huntington National Bank now owns 4,161 shares of the company’s stock valued at $96,000 after acquiring an additional 871 shares during the last quarter. ING Groep NV increased its stake in Kenvue by 23.6% in the third quarter. ING Groep NV now owns 3,576,616 shares of the company’s stock valued at $82,727,000 after acquiring an additional 681,954 shares during the last quarter. Handelsbanken Fonder AB increased its stake in Kenvue by 2.9% in the fourth quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company’s stock valued at $15,846,000 after acquiring an additional 21,222 shares during the last quarter. Alberta Investment Management Corp grew its stake in shares of Kenvue by 23.2% during the fourth quarter. Alberta Investment Management Corp now owns 582,895 shares of the company’s stock valued at $12,445,000 after buying an additional 109,700 shares during the last quarter. Finally, Empower Advisory Group LLC bought a new position in shares of Kenvue during the fourth quarter valued at about $48,252,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE opened at $23.31 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The company has a 50-day simple moving average of $21.31 and a two-hundred day simple moving average of $22.18. The firm has a market capitalization of $44.68 billion, a PE ratio of 43.97, a price-to-earnings-growth ratio of 2.62 and a beta of 1.45.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.52%. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Wall Street Analyst Weigh In

KVUE has been the topic of a number of recent research reports. Citigroup reduced their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $21.00 to $26.00 in a research note on Monday, January 6th. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and reduced their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Barclays reduced their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Kenvue presently has an average rating of “Hold” and an average target price of $23.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.